MDTC34 Stock Overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for MDTC34 from our risk checks.
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$212.34 |
| 52 Week High | US$238.47 |
| 52 Week Low | US$172.00 |
| Beta | 0.80 |
| 1 Month Change | 1.62% |
| 3 Month Change | -2.21% |
| 1 Year Change | -3.67% |
| 3 Year Change | -36.17% |
| 5 Year Change | n/a |
| Change since IPO | 51.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDTC34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 2.8% | 0.8% | -1.1% |
| 1Y | -3.7% | -0.7% | 10.3% |
Return vs Industry: MDTC34 underperformed the BR Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: MDTC34 underperformed the BR Market which returned 10.3% over the past year.
Price Volatility
| MDTC34 volatility | |
|---|---|
| MDTC34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: MDTC34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDTC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products.
Medtronic plc Fundamentals Summary
| MDTC34 fundamental statistics | |
|---|---|
| Market cap | R$566.82b |
| Earnings (TTM) | R$21.65b |
| Revenue (TTM) | R$166.55b |
26.2x
P/E Ratio3.4x
P/S RatioIs MDTC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDTC34 income statement (TTM) | |
|---|---|
| Revenue | US$32.32b |
| Cost of Revenue | US$11.08b |
| Gross Profit | US$21.24b |
| Other Expenses | US$17.04b |
| Earnings | US$4.20b |
Last Reported Earnings
Jan 26, 2024
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | 3.16 |
| Gross Margin | 65.72% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 48.3% |
How did MDTC34 perform over the long term?
See historical performance and comparison